Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Merck Adds To Cancer Research Aura With Vertex Aurora Kinase Inhibitors

  • News

Executive Summary

Merck and Vertex expect to begin clinical trials of the aurora kinase inhibitor anticancer agent VX-680 during the second half of the year

You may also be interested in...



“Bio-buck” Deals A Good Risk-Sharing Strategy, Pharma Execs Say At BIO

Bio-buck deals, those back-end-loaded, early-stage collaborations that grab headlines because of the big dollars promised, are a win-win risk share, big pharma execs say

Merck Enters Macular Degeneration Field With Alnylam Deal

Merck's first product to treat age-related macular degeneration will enter clinical trials in the second half of 2005 through a development and commercialization agreement with Alnylam Pharmaceuticals

Merck Enters Macular Degeneration Field With Alnylam Deal

Merck's first product to treat age-related macular degeneration will enter clinical trials in the second half of 2005 through a development and commercialization agreement with Alnylam Pharmaceuticals

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS044239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By